Showing strength in troubled times


Madrid – When Chinese Premier Wen Jiabao met his Spanish colleague Jose Luis Rodriguez Zapatero on August 31st, he talked about the Mediterranean country’s role as an important economic partner for China, and said cooperation should be strengthened in key strategic areas like renewable energy, aerospace technology and biotechnology.
The burgeoning life sciences sector in Spain has gained renown beyond the country’s borders in the past few years. A symbol for the healthy state of the industry there is BioSpain. Since it was first launched in 2003, the fair has become the leading biotechnology event in Southern Europe. More than 160 companies and institutions will exhibit in Pamplona from September 29th-October 1st. The partnering event, organised by EBD Group, will bring together 1,200 delegates from over 700 companies.
BioSpain’s steady growth is mirrored by the Spanish biotechnology industry, which is one of the few economic powerhouses in a country battered by the housing bust and the financial crisis. The absolute size of the field is still small compared to other sectors, but its relevance for the future of the Spanish economy is far greater. Investments in biotech research and development have doubled in three years, according to the annual report (2009) published by the Spanish Bioindustry Association (ASEBIO). Not only are investments rising, but revenues as well. Bioindustry turnover in Spain reached a31.1bn in 2008, an 18.9% increase over the previous year. 942 companies engaged in bio­technology-related activities in 2008, and they had a growth rate of 23.3% over the previous year. Of these, 305 companies are dedicated biotech companies. Total employment topped 108,000 last year, 4.3% higher than in 2008. "We are very pleased with the evolution shown by the biotech market in Spain,”says ASEBIO Chairman José María Fernández Sousa-Faro. Some champions are emerging. In the drugs’ area, four companies that have already launched products stand out:

PharmaMar with Yondelis against soft tissue sarcoma and ovarian cancer,

Palau Pharma together with Iberhospitex in the cardiovascular area, GP-Pharm with Lutrate Depot against prostate cancer, and Merck’s Atacicept for treating lupus.



Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...



Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...



Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...



Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).



Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...



Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...



Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...



Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...



Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%


  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%


  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%


  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues